Suppr超能文献

老年男性低睾酮血症:我们应该进行治疗吗?

Hypotestosteronaemia in the aging male: should we treat it?

作者信息

Christe Nora, Meier Christoph A

机构信息

Dept. of Internal Medicine and Specialities, Triemli Hospital, Zürich, Switzerland.

出版信息

Swiss Med Wkly. 2015 Nov 24;145:w14216. doi: 10.4414/smw.2015.14216. eCollection 2015.

Abstract

The term male hypogonadism is defined as the failure to maintain physiological concentrations of testosterone, a physiological quantity of sperm or the combination of both. Aetiologically, androgen deficiency can originate from the testes (primary hypogonadism) or from the hypothalamic-pituitary regulation of the testicular function (secondary hypogonadism). The causes of hypogonadism are very diverse and may be genetically determined (e.g. Klinefelter's syndrome) or acquired (tumours, infections, haemochromatosis). Classical hypogonadism linked to an underlying disease, such as a pituitary tumour, is a distinct indication for androgen substitution. But how about the aging male? It is known that there is a highly variable age-related decline in testosterone levels; whether this represents a variation of normality or has a true disease value requiring therapy has been disputed over more than a decade. The key questions surrounding this debate concern not only the age-dependent threshold for serum testosterone but, more importantly, the risks and benefits of testosterone replacement therapy in the aging male. We searched the literature for randomised controlled trials of testosterone administration in aging males with a size of at least 100 patients and a follow-up of at least 6 months, and identified eight studies. These studies mostly tried to evaluate the effect of testosterone on bone density, muscle strength and body composition, rather than clinically meaningful endpoints. Moreover, these trials have provided evidence for relevant cardiovascular adverse events in elderly men. This supports the need for further studies to define the treatment threshold for testosterone levels in the aging male, as well as with regard to the long-term risks and relevant benefits of testosterone therapy in this population. Until we have more solid data in aging males, testing for testosterone deficiency and testosterone replacement should remain reserved for patients with predisposing conditions, symptoms and signs of bona fide hypogonadism.

摘要

男性性腺功能减退这一术语的定义是无法维持睾酮的生理浓度、正常数量的精子或两者兼具。从病因学角度来看,雄激素缺乏可源于睾丸(原发性性腺功能减退)或源于下丘脑 - 垂体对睾丸功能的调节(继发性性腺功能减退)。性腺功能减退的病因非常多样,可能由遗传因素决定(如克兰费尔特综合征)或后天获得(肿瘤、感染、血色素沉着症)。与潜在疾病(如垂体肿瘤)相关的典型性腺功能减退是雄激素替代治疗的明确指征。但老年男性的情况如何呢?众所周知,睾酮水平会随年龄增长出现高度可变的下降;这是正常的变化还是具有需要治疗的真正疾病价值,十多年来一直存在争议。这场辩论的关键问题不仅涉及血清睾酮的年龄依赖性阈值,更重要的是,老年男性睾酮替代治疗的风险和益处。我们在文献中搜索了针对至少100例患者且随访至少6个月的老年男性睾酮给药的随机对照试验,共确定了八项研究。这些研究大多试图评估睾酮对骨密度、肌肉力量和身体成分的影响,而非具有临床意义的终点指标。此外,这些试验已为老年男性相关心血管不良事件提供了证据。这支持了进一步研究的必要性,以确定老年男性睾酮水平的治疗阈值,以及该人群睾酮治疗的长期风险和相关益处。在我们获得更多关于老年男性的确切数据之前,对于睾酮缺乏的检测和睾酮替代治疗应仅保留给具有易患条件、真正性腺功能减退症状和体征的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验